Kobe Minimally Invasive Cancer Center
1 clinical trials · Sponsor
◉ Watch Kobe Minimally Invasive Cancer Center
| Record | Firm | Date |
|---|---|---|
| Pembrolizumab + Platinum Doublets Without Radiation for Programmed Death-ligand 1 (PD-L1) ≥50% Locally Advanced NSCLC (NCT04153734) | Kobe Minimally Invasive Cancer Center | 2019-12-01 |
Track Kobe Minimally Invasive Cancer Center automatically
Every clearance here is in the API, with alerts when new ones post.